National reach AOM Infusion holds a pharmacy license in all 50 states and is expanding therapy solutions and innovative platforms to reach more patients nationwide, signaling potential for enterprise-level IVIG and specialty infusion partnerships across multiple regions.

Strategic partnerships Recent collaborations with Kedrion Biopharma and inclusion in its limited distribution network for QIVIGY indicate a readiness to scale high-demand immunoglobulin therapies and cross-sell complementary infusion services.

Growth funding Significant investment from Revelstoke Capital Partners in 2025 suggests expanded capacity, infrastructure, and technology investments that can support expanded client onboarding, managed services, and scalable IVIG programs.

Expansion footprint Office expansion to New York City and broader geographic presence create opportunities to offer centralized operations, regional care coordination, and faster service delivery to high-density markets.

Tech-enabled care Adoption of modern tech stack including Adobe Experience Cloud, AI tools, messaging platforms, and secure device management indicates potential for leveraging digital engagement, patient portals, and streamlined referral-to-infusion workflows for potential health system and payer partnerships.